- Details
- Neal Shore discusses the ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment strateg...
|
- Details
- Tanya Stoyanova discusses research on Trop2's role in prostate cancer, published in Nature Scientific Reports. Collaborating with Drs. Michael Liss and Jim Brooks, the study reveals Trop2 as a high-potential therapeutic target due to its overexpression in various epithelial cancers, including prostate cancer, where it's linked to aggressive behavior. Their work, validated in a large patient cohort...
|
- Details
- Historically, conventional imaging techniques have been used for the assessment of clinical progression in biochemical recurrence (BCR). However, these imaging technologies have limited sensitivity at low PSA values (<10 ng/mL). Next-generation imaging (NGI) technologies may overcome the sensitivity limitations associated with low PSA values and offer improved diagnostic accuracy for identifying B...
|
- Details
- Alicia Morgans, Mark Markowski, and Emmanuel Antonarakis discuss research on high-dose testosterone therapy for metastatic castration-resistant prostate cancer, inspired by Sam Denmeade's paradoxical approach. The COMBAT trial, a phase II study, explored the efficacy of combining bipolar androgen therapy (BAT) with the immune checkpoint inhibitor nivolumab, revealing notable PSA response rates and...
|
- Details
- Boris Hadaschik discusses the ongoing PRIMORDIUM phase three trial. The study explores the efficacy of adding six months of apalutamide to ADT in men with high-risk biochemical recurrence post-prostatectomy, evidenced by PSMA-PET imaging. This innovative trial integrates PET imaging not just at baseline but as a primary endpoint, marking a significant leap in utilizing advanced diagnostics to guid...
|
- Details
- Alicia Morgans interviews Neeraj Agarwal about the CONTACT-02 trial, a phase III study that explores the combination of cabozantinib and atezolizumab in patients with metastatic castrate-resistant prostate cancer (mCRPC) who have progressed on one novel hormonal therapy (NHT). This trial, which focuses on patients with extrapelvic soft tissue metastasis, has shown a significant reduction in the ri...
|
- Details
- Zach Klaassen and Daniel George discuss the highlights from ASCO GU 2024 including the BRCAAway trial, a study focusing on the combination of PARP inhibitors and novel hormonal agents for treating metastatic castration-resistant prostate cancer. Dr. George explains the trial's innovative design, which explored the efficacy of abiraterone and olaparib, both separately and in combination, in patient...
|
- Details
- Andrea Miyahira and Alex Wyatt discuss a study on de novo metastatic prostate cancer, revealing its genomic complexity through multiregion sampling. Published in Nature Cancer, the research highlights the polyclonality of the disease and its implications for clinical genotyping. By examining multiple regions from patients' prostates and lymph nodes, the study uncovers significant genomic heterogen...
|
- Details
- Massimo (Max) Loda discusses his team’s research on the role of the microenvironment in prostate cancer progression, published in Nature Communications. The study focuses on the stroma's significance in prostate carcinogenesis. Utilizing mouse models and human tumors, they performed single-cell RNA sequencing to analyze stromal cells in different stages of prostate cancer. The research revealed di...
|
- Details
- Zachary Klaassen interviews Henrik Grönberg about the ProBio trial, presented at ESMO 2023. The ProBio trial, designed in 2019, is a platform trial aimed at determining the optimal treatment sequence for metastatic prostate cancer and identifying predictive biomarkers for treatment efficacy. Unique to ProBio is its use of circulating tumor DNA as a biomarker for assigning patients to experimental...
|
